期刊
BRAIN RESEARCH BULLETIN
卷 168, 期 -, 页码 100-109出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2020.12.017
关键词
Parkinson's disease; PD treatment; New drug development; Clinical trials; alpha-Synuclein
资金
- National Natural Science Foundation of China [81773925, 81730096]
- Drug Innovation Major Project [2018ZX09711-001-001-001]
Current treatments for Parkinson's disease mainly rely on dopaminergic drugs, which are symptomatic and have limitations due to side effects. Recent studies have focused on new molecular mechanisms and immunotherapy, as well as common pathological mechanisms shared with Alzheimer's Disease and diabetes.
Current treatments for Parkinson's disease (PD) are mainly dopaminergic drugs. However, dopaminergic drugs are only symptomatic treatments and limited by several side effects. Recent studies into drug development focused on emerging new molecular mechanisms, including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, nuclear receptor-related 1 (Nurr1), adenosine receptor A2, nicotine receptor, metabotmpic glutamate receptors (mGluRs), and glucocerebrosidase (GCase). Also, immunotherapy and common pathological mechanisms shared with Alzheimer's Disease (AD) and diabetes have attracted much attention. In this review, we summarized the development of preclinical and clinical studies of novel drugs and the improvement of dopaminergic drugs to provide a prospect for PD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据